MTOR and hepatocellular carcinoma: Antineoplastic effects have also been proposed for mTOR inhibitors [108–110] and everolimus marketed as Afinitor (Novartis Pharma AG; Basel, Switzerland) is already approved for a number of cancer indications and may have further relevance in the setting of posttransplant malignancy and HCC recurrence.